NG-350A
AXP000038.1 · Oncolytic virus
- Platform
- adenovirus (Ad11p/Ad3 group B chimera, T-SIGn vector)
- Originator
- PsiOxus Therapeutics
- Sponsor
- Akamis Bio
Names
| Name | Type | Source |
|---|---|---|
| NG-350A | preferred name, code | curator, ncit |
Virus
- Role
- Oncolytic
- Family
- Adenoviridae
- Virus
- human adenovirus 11 (NCBI Taxonomy 10541)
- Strain
- Ad11p/Ad3 group B chimera (T-SIGn)
- Replication
- conditionally replicating
- Modifications
- enadenotucirev backbone carrying a transgene cassette
- Transgenes
- anti-CD40 agonist antibody
- Route
- intravenous, intratumoral
- Source
- evidence
Cross-references
- NCI Thesaurus
- C159599
Approvals
No regulatory approval recorded.
Clinical trials (4)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT06459869 | NG-350A Plus Chemoradiotherapy for Locally Advanced Rectal Cancer | Active not recruiting | Phase 1 | 2025-04-07 | 2027-01-30 | 33 | Locally Advanced Rectal Cancer (LARC) |
| NCT05165433 | Study of NG-350A Plus Pembrolizumab in Metastatic or Advanced Epithelial Tumours (FORTIFY) | Completed | Phase 1 | 2022-04-13 | 2025-08-29 | 14 | Epithelial Tumor; Metastatic Cancer |
| NCT04787991 | Exploratory Platform Trial to Evaluate Immunotherapy Combinations With Chemotherapy for the Treatment of Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma | Completed | Phase 1 | 2021-08-09 | 2024-11-12 | 45 | Metastatic Pancreatic Adenocarcinoma |
| NCT03852511 | First in Human Study of NG-350A (an Oncolytic Adenoviral Vector Which Expresses an Anti-CD40 Antibody) | Completed | Phase 1 | 2019-02-19 | 2022-02-04 | 28 | Epithelial Tumor; Metastatic Cancer |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 39414325 | First-in-human clinical outcomes with NG-350A, an anti-CD40 expressing tumor-selective vector designed to remodel immunosuppressive tumor microenvironments. | Journal for immunotherapy of cancer | 2024 | cited by trial NCT05165433 |
| PMID 36897458 | A tumor-selective adenoviral vector platform induces transient antiphospholipid antibodies, without increased risk of thrombosis, in phase 1 clinical studies. | Investigational new drugs | 2023 | cited by trial NCT03852511 |
Notes
Enadenotucirev (AXP000012) backbone armed with a full-length agonistic anti-CD40 antibody; separate construct, separate program. PsiOxus renamed itself Akamis Bio in January 2023.
How to cite
NG-350A (AXP000038.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000038.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.